要高度重视免疫检查点抑制剂相关心血管不良反应的诊治  

Pay attention to diagnosis and treatment of cardiovascular adverse reactions associated with immune checkpoint inhibitors

作　　者：詹洪吉 刘红霞 谭梦琴 王福军 ZHAN Hongji;LIU Hongxia;TAN Mengqin;WANG Fujun(Department of Cardiology,Xiangxi Tujia and Miao Autonomous Prefecture People's Hospital,Jishou Hunan 416000;Emergency Medical Center,Hunan University of Medicine General Hospital,Huaihua Hunan 418000;Cardiac Center,Geriatric Hospital of Hainan,Haikou Hainan 571100,China)

机构地区：[1]湘西土家族苗族自治州人民医院心内科,湖南吉首416000 [2]湖南医药学院总医院急救医学中心,湖南怀化418000 [3]海南省老年病医院心脏中心,海南海口571100

出　　处：《实用心电学杂志》2024年第6期541-547,共7页Journal of Practical Electrocardiology

基　　金：湖南省卫生健康委员会科研资助项目(202203014682);中国药文化研究会医药科教分会科研一般项目(2024KXJS0004)。

摘　　要：免疫检查点抑制剂(immune checkpoint inhibitors,ICIs)在肿瘤免疫治疗中占据了核心地位,极大地改善了肿瘤患者的预后。但随着临床实践的不断深入,发现ICIs在激活免疫系统的同时,还会引起各种不良反应,尤其是导致多种心血管毒性,使心血管死亡率升高。本文综述了ICIs诱发心血管毒性的临床表现形式、发生机制、诊断及防治方法等,为预防心血管损伤、改善心脏功能提供依据。Immune checkpoint inhibitors(ICIs)occupy a core position in tumor immunotherapy,and greatly improve the prognosis of tumor patients.However,with the deepening of clinical practice,it has been found that ICIs can not only activate the immune system,but also cause many adverse reactions,especially leading to a variety of cardiovascular toxicity and increased cardiovascular mortality.This paper reviews the clinical manifestations,pathogenesis,diagnosis and treatment,etc.of ICIs-induced cardiovascular toxicity,which provides evidences for preventing cardiovascular injury and improving cardiac function.

关 键 词：免疫检查点抑制剂 心脏毒性 免疫相关不良事件 肿瘤免疫疗法 肿瘤心脏病学 

分 类 号：R542.2[医药卫生—心血管疾病]